369 related articles for article (PubMed ID: 25251602)
1. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
Wen H; Cho HR; Yun T; Kim H; Park CK; Lee SH; Choi SH; Park S
J Neurochem; 2015 Jan; 132(2):183-93. PubMed ID: 25251602
[TBL] [Abstract][Full Text] [Related]
2. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
[TBL] [Abstract][Full Text] [Related]
3. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.
Reitman ZJ; Jin G; Karoly ED; Spasojevic I; Yang J; Kinzler KW; He Y; Bigner DD; Vogelstein B; Yan H
Proc Natl Acad Sci U S A; 2011 Feb; 108(8):3270-5. PubMed ID: 21289278
[TBL] [Abstract][Full Text] [Related]
4. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
5. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Rohle D; Popovici-Muller J; Palaskas N; Turcan S; Grommes C; Campos C; Tsoi J; Clark O; Oldrini B; Komisopoulou E; Kunii K; Pedraza A; Schalm S; Silverman L; Miller A; Wang F; Yang H; Chen Y; Kernytsky A; Rosenblum MK; Liu W; Biller SA; Su SM; Brennan CW; Chan TA; Graeber TG; Yen KE; Mellinghoff IK
Science; 2013 May; 340(6132):626-30. PubMed ID: 23558169
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
[TBL] [Abstract][Full Text] [Related]
7. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
8. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
[TBL] [Abstract][Full Text] [Related]
9. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
Johannessen TA; Mukherjee J; Viswanath P; Ohba S; Ronen SM; Bjerkvig R; Pieper RO
Mol Cancer Res; 2016 Oct; 14(10):976-983. PubMed ID: 27430238
[TBL] [Abstract][Full Text] [Related]
10. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.
Emir UE; Larkin SJ; de Pennington N; Voets N; Plaha P; Stacey R; Al-Qahtani K; Mccullagh J; Schofield CJ; Clare S; Jezzard P; Cadoux-Hudson T; Ansorge O
Cancer Res; 2016 Jan; 76(1):43-9. PubMed ID: 26669865
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment.
Zhang N; Zheng B; Yao X; Huang X; Du J; Shen Y; Huang Z; Chen J; Lin Q; Lan W; Lin W; Ma W
Biochem Biophys Res Commun; 2021 Apr; 551():38-45. PubMed ID: 33714758
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.
Gao M; Zhu H; Fu L; Li Y; Bao X; Fu H; Quan H; Wang L; Lou L
Cancer Sci; 2019 Oct; 110(10):3306-3314. PubMed ID: 31361380
[TBL] [Abstract][Full Text] [Related]
14. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
[TBL] [Abstract][Full Text] [Related]
15. An R132H mutation in isocitrate dehydrogenase 1 enhances p21 expression and inhibits phosphorylation of retinoblastoma protein in glioma cells.
Miyata S; Urabe M; Gomi A; Nagai M; Yamaguchi T; Tsukahara T; Mizukami H; Kume A; Ozawa K; Watanabe E
Neurol Med Chir (Tokyo); 2013; 53(10):645-54. PubMed ID: 24077277
[TBL] [Abstract][Full Text] [Related]
16. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
[TBL] [Abstract][Full Text] [Related]
17. Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
Fathi AT; Nahed BV; Wander SA; Iafrate AJ; Borger DR; Hu R; Thabet A; Cahill DP; Perry AM; Joseph CP; Muzikansky A; Chi AS
Oncologist; 2016 Feb; 21(2):214-9. PubMed ID: 26834160
[TBL] [Abstract][Full Text] [Related]
18. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).
Grassian AR; Lin F; Barrett R; Liu Y; Jiang W; Korpal M; Astley H; Gitterman D; Henley T; Howes R; Levell J; Korn JM; Pagliarini R
J Biol Chem; 2012 Dec; 287(50):42180-94. PubMed ID: 23038259
[TBL] [Abstract][Full Text] [Related]
19. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
20. Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Dang L; Su SM
Annu Rev Biochem; 2017 Jun; 86():305-331. PubMed ID: 28375741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]